文献速递肝胆胰外科

远端胰腺切除术基准结局定义:法国多中心研究结果

Defining Benchmark Outcomes for Distal Pancreatectomy: Results of a French Multicentric Study.
PubMed 文献 · Ann Surg · 2022-06-28

该法国多中心研究纳入2014至2018年21家胰腺外科专家中心所有因可切除良恶性肿瘤行远端胰腺切除术的患者,以无显著合并症的低危队列建立18项结局基准,并在高危、微创和良性肿瘤队列中验证。研究确定微创入路基准率≥36.8%,术后死亡率、重大并发症(≥3a级)和临床显著胰瘘基准截点分别为0%、≤27%和≤28%,再入院率≤16%。

要点

  • 低危队列建立远端胰腺切除术18项结局基准,微创入路基准率≥36.8%。
  • 术后死亡率0%、重大并发症≤27%、临床显著胰瘘≤28%、再入院≤16%。
  • 胰腺腺癌R0切除、1年无病生存和3年总生存基准截点分别为≥75%、≥69.5%和≥66%。

核心结论

  • 该大规模研究首次对远端胰腺切除术结局进行基准分析,提供了稳健且标准化的数据,可用于比较外科医生、中心、研究和手术技术。

研究设计与样本

  • 多中心研究纳入2014至2018年21家法国胰腺外科专家中心所有因可切除良恶性肿瘤行远端胰腺切除术的患者,共识别1188例,筛选749例低危患者建立基准截点。

主要发现

  • 微创入路基准率为≥36.8%,术后死亡率、重大并发症(≥3a级)和临床显著胰瘘率的基准截点分别为0%、≤27%和≤28%,再入院率≤16%。
  • 胰腺腺癌患者R0切除、1年无病生存和3年总生存的基准截点分别为≥75%、≥69.5%和≥66%。
  • 高危队列微创入路率为34.1%,低于基准截点≥36.8%;良性肿瘤组所有基准截点均得到遵守。
  • 基准病例比例与远端胰腺切除术结局相关,低危患者占多数的中心结果劣于处理复杂病例的中心。

关键数值与推荐

  • 微创入路基准率≥36.8%。
  • 术后死亡率基准截点0%。
  • 重大并发症(≥3a级)基准截点≤27%。
  • 临床显著胰瘘率基准截点≤28%。
  • 再入院率基准截点≤16%。

临床怎么用

  • 可将这些基准截点用于比较不同外科医生、中心、研究和手术技术的远端胰腺切除术结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Defining robust and standardized outcome references for distal pancreatectomy (DP) by using Benchmark analysis. BACKGROUND: Outcomes after DP are recorded in medium or small-sized studies without standardized analysis. Therefore, the best results remain uncertain. METHODS: This multicenter study included all patients undergoing DP for resectable benign or malignant tumors in 21 French expert centers in pancreas surgery from 2014 to 2018. A low-risk cohort defined by no significant comorbidities was analyzed to establish 18 outcome benchmarks for DP. These values were tested in high risk, minimally invasive and benign tumor cohorts. RESULTS: A total of 1188 patients were identified and 749 low-risk patients were screened to establish Benchmark cut-offs. Therefore, Benchmark rate for mini-invasive approach was ≥36.8%. Benchmark cut-offs for postoperative mortality, major morbidity grade ≥3a and clinically significant pancreatic fistula rates were 0%, ≤27%, and ≤28%, respectively. The benchmark rate for readmission was ≤16%. For patients with pancreatic adenocarcinoma, cut-offs were ≥75%, ≥69.5%, and ≥66% for free resection margins (R0), 1-year disease-free survival and 3-year overall survival, respectively. The rate of mini-invasive approach in high-risk cohort was lower than the Benchmark cut-off (34.1% vs ≥36.8%). All Benchmark cut-offs were respected for benign tumor group. The proportion of benchmark cases was correlated to outcomes of DP. Centers with a majority of low-risk patients had worse results than those operating complex cases. CONCLUSION: This large-scale study is the first benchmark analysis of DP outcomes and provides robust and standardized data. This may allow for comparisons between surgeons, centers, studies, and surgical techniques.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Durin T, Marchese U, Sauvanet A, et al. Defining Benchmark Outcomes for Distal Pancreatectomy: Results of a French Multicentric Study. Ann Surg. 2022. PMID: 35762617. doi:10.1097/SLA.0000000000005539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。